Trial Profile
A Phase 1 Evaluation of the Safety and Tolerability of TAK-228 in Combination With TAK-117 and Paclitaxel in Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Aug 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Sapanisertib (Primary) ; Serabelisib (Primary)
- Indications Advanced breast cancer; Brain metastases; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Uterine cancer
- Focus Adverse reactions
- 14 Jul 2022 Preliminary efficacy results(n=19) of Phase I dose escalation study assessing the safety and efficacy of paclitaxel, sapanisertib, and serabelisib in Patients with previously treated advanced solid tumors published in the Gynecologic Oncology.
- 24 Aug 2021 Planned End Date changed from 1 Jul 2021 to 1 Jul 2022.
- 08 Jun 2021 Final results of phase 1 evaluation of the safety and clinical activity of sapanisertib in combination with serabelisib and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer presented at the 57th Annual Meeting of the American Society of Clinical Oncology